AP  —  Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment. The once-daily version of the pill was in early-stage testing, with researchers trying to figure out the best

Tag-uri: Pfizer